More Stories

Informist, Tuesday, May 19, 2026

 

Please click here to read all liners published on this story

--Mankind Pharma Jan-Mar consol net profit INR 5.54 bln
--Analysts saw Mankind Pharma Jan-Mar consol net profit at INR 4.04 bln
--Mankind Pharma Jan-Mar consol revenue INR 34.43 bln
--Analysts saw Mankind Pharma Jan-Mar consol revenue at INR 34.15 bln
--Mankind Pharma Jan-Mar consol PAT INR 5.54 bln vs INR 4.21 bln year ago
--Mankind Pharma Jan-Mar consol revenue INR 34.43 bln vs INR 30.79 bln yr ago
--Mankind Pharma to invest up to INR 5 bln in arm Mankind Medicare
--Mankind Pharma reappoints Satish K Sharma as whole time director for 5 yrs
--Mankind Pharma FY26 consol PAT INR 19.13 bln vs INR 19.91 bln yr ago
--Mankind Pharma FY26 consol revenue INR 142.78 bln vs INR 122.07 bln yr ago
--Mankind Pharma Jan-Mar consol EBITDA INR 9.10 bln vs INR 6.86 bln yr ago
--Mankind Pharma Jan-Mar consol EBITDA margin 26.4% vs 22.3% year ago
--Mankind Pharma Jan-Mar consol gross margin 72.2% vs 71.6% year ago
--Mankind Pharma Q4 domestic revenue INR 28.86 bln vs INR 25.44 bln yr ago
--Mankind Pharma Q4 revenue from exports INR 5.57 bln vs INR 5.35 bln yr ago

 

By Eshitva Prakash and Gunjan Rajput

 

NEW DELHI – Mankind Pharma Ltd. reported the sharpest year-on-year rise in two years in its consolidated net profit for the March quarter, beating analysts' estimates convincingly. Its bottom line was boosted by decent growth in revenue and a benign rise in expenditure. Its net profit rose for the second consecutive quarter after declining for four quarters on a year-on-year basis.

The drugmaker's consolidated net profit for the quarter rose nearly 32% on year to INR 5.54 billion from INR 4.21 billion in the year-ago quarter, beating analysts' consensus estimate of INR 4.04 billion. The consolidated revenue for the quarter increased nearly 12% on year to INR 34.43 billion from INR 30.79 billion a year ago. Analysts had estimated the revenue at INR 34.15 billion.

 

The company's total expenditure for the March quarter was INR 28.78 billion, up just 2% on year, the slowest year-on-year rise for the company since it was listed. Total costs dropped 5% sequentially. The finance cost decreased nearly 26% on year to INR 1.42 billion and its depreciation and amortisation expense declined 3.4% to INR 2.23 billion. Meanwhile, the cost of purchase of stock-in-trade rose 21% to INR 4.98 billion. The cost of raw materials consumed was up marginally on year at INR 5.55 billion and the employee benefit expenses rose 5% on year to INR 7.52 billion. Other expenses declined marginally on year to INR 8.03 billion.

 

The company reported consolidated earnings before interest, tax, depreciation, and amortisation of INR 9.10 billion, up nearly 33% on year. Its EBITDA margin expanded to 26.4% from 22.3% in the year-ago quarter. The consolidated gross margin also improved to 72.2% from 71.6% in the corresponding quarter of the financial year 2024-25 (Apr-Mar). As on Mar. 31, the company had a net debt of INR 39.32 billion with its net-debt to EBITDA ratio at 1.1.   

 

The company drew revenues of INR 28.86 billion from its domestic business, up over 13% on year but down over 5% sequentially. This growth was supported by strong growth in the Bharat Serums and Vaccines speciality business, the company said in an investor presentation. At 8.7%, the company's secondary sales growth in the March quarter underperformed the Indian pharmaceutical market, which grew at a little over 10%. Its business was boosted by strong performance in chronic therapy, which in turn was supported by sales growth of almost 15% in cardiac therapy and nearly 12% in anti-diabetes therapy. However, its anti-infective therapy portfolio saw muted growth. 

 

In the March quarter, the company's revenues from exports were slightly higher on year at INR 5.57 billion. The company said revenue from international business was muted due to geopolitical headwinds. Mankind Pharma, excluding Bharat Serums and Vaccines, has launched four new products in FY26 in the US, taking the total number of products launched in the country to 48.

 

The Consumer Healthcare business of the company reported a 20% year-on-year rise in revenue to INR 2.13 billion. Manforce, PregaNews, Gas-o-fast and Nimulid drugs were key growth drivers, according to the company. There was healthy growth in secondary sales for Gas-o-fast, PregaNews, and Ova news, the company said.

 

For FY26, the company reported a consolidated net profit of INR 19.13 billion, down nearly 4%. Its revenue from operations rose almost 17% to INR 142.78 billion. The board reappointed Satish Kumar Sharma as whole-time director for five years from Sept. 23. The company will invest INR 5 billion in its subsidiary, Mankind Medicare Pvt. Ltd., in cash for capacity expansion and setting up a plant.  

 

Mankind Pharma reported its March quarter earnings after market hours Tuesday. Its shares ended slightly lower from Monday at INR 2,492.60 on the National Stock Exchange.  End

 

Edited by Rajeev Pai

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.